Compare MFA & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFA | MGTX |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.0M | 881.7M |
| IPO Year | 1998 | 2018 |
| Metric | MFA | MGTX |
|---|---|---|
| Price | $5.78 | $9.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $12.58 | ★ $27.75 |
| AVG Volume (30 Days) | ★ 2.8M | 607.2K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | ★ 25.90% | N/A |
| EPS Growth | ★ 58.54 | 33.02 |
| EPS | N/A | ★ 0.68 |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | N/A | $314.19 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.97 |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $5.55 | $6.62 |
| 52 Week High | $10.43 | $15.35 |
| Indicator | MFA | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 27.56 | 43.56 |
| Support Level | N/A | $8.80 |
| Resistance Level | $6.87 | $10.08 |
| Average True Range (ATR) | 0.24 | 0.53 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 18.35 | 49.03 |
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets; and Lima One.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.